Copiktra (duvelisib) vs Darvias (darinaparsin) ()
Copiktra (duvelisib) vs Darvias (darinaparsin) ()
Copiktra (duvelisib) is a dual inhibitor of phosphoinositide 3-kinase (PI3K) used primarily for the treatment of chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and follicular lymphoma. Darzalex (daratumumab), which you may be referring to as Darvias, is a CD38-directed cytolytic antibody indicated for multiple myeloma, and it works by targeting and killing CD38-expressing cancer cells. When choosing between these medications, it is essential to consider the specific type of blood cancer being treated, as each medication is tailored to different disease mechanisms and has distinct indications and efficacy profiles.
Difference between Copiktra and Darvias (darinaparsin)
| Metric | Copiktra (duvelisib) | Darvias (darinaparsin) |
|---|---|---|
| Generic name | duvelisib | darinaparsin |
| Indications | Chronic lymphocytic leukemia (CLL), Small lymphocytic lymphoma (SLL), Follicular lymphoma (FL) | Currently in clinical trials for various cancers including lymphoma and solid tumors |
| Mechanism of action | PI3K inhibitor, targets the delta and gamma isoforms of PI3K | Organic arsenic compound, exact mechanism not fully understood but believed to induce mitochondrial dysfunction and apoptosis |
| Brand names | Copiktra | Darvias (under investigation, not yet a brand name) |
| Administrative route | Oral | Intravenous (IV) |
| Side effects | Diarrhea, neutropenia, rash, fatigue, pyrexia, cough, anemia, nausea, upper respiratory infection, pneumonia | Not fully characterized, but potential side effects include fatigue, nausea, vomiting, diarrhea, and hematologic toxicities |
| Contraindications | None known specifically, use with caution in patients with severe active infections or history of intestinal perforation | Not fully characterized, likely contraindicated in patients with hypersensitivity to arsenic |
| Drug class | Antineoplastic, PI3K inhibitor | Antineoplastic, organic arsenic compound |
| Manufacturer | Verastem, Inc. | ZIOPHARM Oncology |
Efficacy
Copiktra (Duvelisib) Efficacy in Treating Lymphoma
Copiktra (duvelisib) is an oral inhibitor of phosphoinositide 3-kinase (PI3K), and it has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and follicular lymphoma (FL) after at least two prior systemic therapies. The efficacy of Copiktra in treating lymphoma was demonstrated in clinical trials, where it showed an ability to reduce tumor burden and prolong progression-free survival in a subset of patients. For instance, in the DUO trial, a phase III study, duvelisib significantly improved the median progression-free survival compared to ofatumumab in patients with relapsed or refractory CLL/SLL.
For FL, the approval was based on a single-arm, multicenter clinical trial that demonstrated a 42% response rate with Copiktra treatment, with 41% of patients experiencing partial response and 1% achieving complete response. The median duration of response was 9.9 months. These results indicate that Copiktra can be an effective treatment option for patients with FL who have exhausted other therapies.
Darvias (Darinaparsin) Efficacy in Treating Lymphoma
Darvias (darinaparsin) is a novel organic arsenic compound with potential antineoplastic activity. While it is not yet approved by the FDA, darinaparsin has been studied in clinical trials for the treatment of various types of cancer, including lymphoma. The efficacy of darinaparsin in treating lymphoma has been evaluated in a phase II clinical trial for patients with relapsed or refractory Hodgkin's and non-Hodgkin's lymphoma. The results from these studies have suggested some level of activity against these diseases, although the data is limited, and further research is necessary to fully establish its efficacy.
In a study involving patients with peripheral T-cell lymphoma, darinaparsin demonstrated a modest response rate, indicating potential as a treatment for this type of lymphoma. However, the overall response rates in clinical trials have been variable, and darinaparsin has not yet been established as a standard treatment for lymphoma. As such, it remains an investigational drug, and its use in lymphoma is considered off-label until further evidence is obtained and regulatory approvals are granted.
Regulatory Agency Approvals
Copiktra
-
European Medical Agency (EMA), European Union
-
Food and Drug Administration (FDA), USA
Darvias (darinaparsin)
-
Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Access Copiktra or Darvias (darinaparsin) today
If Copiktra or Darvias (darinaparsin) are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us